Collaborations & Alliances

XOMA Enters License Agreement With Novo Nordisk for XMetA

Novo Nordisk acquires exclusive global rights to XMetA program for the treatment of diabetes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

XOMA Corporation has licensed the global development and commercialization rights to its XMetA program of allosteric monoclonal antibodies that up-regulate the insulin receptor to Novo Nordisk. XOMA retains commercialization rights for rare disease indications. Novo Nordisk has an option to add these additional rights in rare diseases to its license. XOMA will receive $5 million in an upfront payment, and the agreement includes up to $290 million in additional milestones. XOMA is also eligible t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters